49 results about "IGFBP7" patented technology

Provided are a pharmaceutical composition for prevention and treatment of a neural disease including at least one selected from the group consisting of mesenchymal stem cells (MSCs), a culture solution of the MSCs, activin A, PF4, decorin, galectin 3, GDF15, glypican 3, MFRP, ICAM5, IGFBP7, PDGF-AA, SPARCL1, thrombospondin-1, WISP1, progranulin, IL-4, a factor inducing expression thereof, and any combination thereof, and a method therefor.

Methods and systems for diagnosing functional and / or structural abnormalities of the heart preceding heart failure, and for predicting the risk of developing heart failure, in a subject comprising measuring a cardiac troponin in a sample and comparing the measurement to a reference value. Other markers, including GDF15 and IGFBP7 are also measured in some embodiments.

The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being treatable with anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.

Methods of identifying specific target molecules for design of anti-angiogenic and vascular targeting approaches are disclosed. Transcriptional profiles of tumor endothelial cells were compared with that of normal resting endothelial cells, normal but angiogenically activated placental endothelial cells, and cultured endothelial cells. Although the majority of transcripts were classified as general angiogenesis markers, 17 genes were identified that show specific overexpression in tumor endothelium. Antibody targeting of four cell-surface expressed or secreted products (vimentin, CD59, HMGB1 and IGFBP7) inhibited angiogenesis in vitro and in vivo. Finally, targeting endothelial vimentin in a mouse tumor model significantly inhibited tumor growth and reduced microvessel density. The results demonstrate the utility of the identification and subsequent targeting of specific tumor endothelial markers for anticancer therapy.

The present invention provides diagnostic methods for predicting the effectiveness of treatment of an hepatocellular carcinoma (HCC) patient with an IGF-1R kinase inhibitor by assessing whether the HCC tumor cells express a high level of AFP, or whether serum levels of AFP protein are high. The present invention also provides diagnostic methods for predicting the effectiveness of treatment of cancer patients with IGF-1R kinase inhibitors, based on a determination of the expression level of IR, IGF-2, IGFBP3 or IGFBP7 in tumor cells, or a 4-gene index calculated using the expression vales for each of these four genes, which can be used to identify tumors that will be sensitive to IGF-1R kinase inhibitors, and also those that will be insensitive. Improved methods for treating cancer patients with IGF-1R kinase inhibitors that incorporate the above methods are also provided.

The present invention relates to a method for identifying a subject being eligible to the administration of at least one medicament selected from the group consisting of a beta blocker, an aldosterone antagonist, a diuretic, and an inhibitor of the renin-angiotensin system. The method is based on the determination of the amount of at least one biomarker selected from the group consisting of GDF-15 (Growth Differentiation Factor 15), endostatin, mimecan, IGFBP7 (IGF binding protein 7), a cardiac Troponin, a BNP-type peptide, uric acid, Gal3 (Galectin-3), osteopontin, sST2 (soluble ST2), PlGF, sFlt-1, P1NP, Cystatin C, Prealbumin, and Transferrin in a sample from a subject suffering from heart failure. Further, the method comprises the step of comparing the, thus, determined amount with a reference amount. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention. The present invention also relates to a system for identifying a subject being eligible to the administration of at least one medicament as disclosed herein and to reagents and kits used in performing the methods as disclosed herein.

The invention relates to antibodies or fragments thereof specific for insulin-like growth factor binding protein-7 (IGFBP7). A method of raising anti-IGFBP7 single domain antibodies is also disclosed and specific antibody clones are described, along with their binding characteristics. The anti-IGFBP7 antibodies may be useful as diagnostic tools for detecting neoplastic diseases involving tumor angiogenesis, and a variety of other angiogenesis associated diseases.

The invention belongs to the field of biological medicine, relates to a specific high-affinity recombinant antibody marking fluorescent microsphere and a preparation method and application thereof and particularly relates to a plug-and-play fluorescence detection card for quick quantitative detection of KIM-1, NGAL, IGFBP7, TIMP-2, IL-18, PCT and cTnI in human urine or blood samples. The method includes: activating fluorescent microspheres; adding the activated fluorescent microspheres into a dialysis bag filled with phosphate buffer to obtain dialyzed fluorescent microsphere solution; adding amino-polyethylene glycol-carboxyl, further activating the fluorescent microsphere solution subjected to secondary dialysis, making with a recombinant antibody, centrifuging after reaction, washing, precipitating, resuspending and precipitating. The fluorescent microsphere has advantages that immunofluorescence reaction lower limit can be remarkably improved to enable sensitivity of a prepared test card to be improved by 10-100 times of that of test cards prepared according to a traditional method, and a test range is remarkably expanded.

Provided are methods of regulating keratinocytes proliferation and differentiation by subjecting keratinocytes to an agent capable of modulating activity or expression of IGFBP7, thereby regulating keratinocytes proliferation and differentiation. Also provided are methods of treating pathologies characterized by hyperproliferative keratinocytes by administering IGFBP7 polypeptide or a polynucleotide encoding IGFBP7 polypeptide to a subject.

Insulin-like growth factor-binding protein 7 (IGFBP7) has been identified herein as a therapeutic target for the treatment or prevention of heart diseases, metabolic diseases, and other related disease or conditions. IGFBP7 inhibitors having IGFBP7 expression and / or activity reducing properties are described herein. Treatment methods, and uses, relating to such IGFBP7 inhibitors for the treatment or prevention of heart failure, IGFBP7-related metabolic diseases, and related diseases or conditions are provided.

Methods and tools are provided for detecting and predicting lung cancer. The methods and tools are based on epigenetic modification due to methylation of genes in lung cancer or pre-lung cancer. The tools can be assembled into kits or can be used seperately. Genes found to be epigentically silenced in association with lung cancer include ACSL6, ALS2CL, APC2, ART-S1, BEX1, BMP7, BNIP3, CBR3, CD248, CD44, CHD5, DLK1, DPYSL4, DSC2, EDNRB, EPB41L3, EPHB6, ERBB3, FBLN2, FBN2, FOXL2, GNAS, GSTP1, HS3ST2, HPN, IGFBP7, IRF7, JAM3, LOX, LY6D, LY6K, MACF1, MCAM, NCBP1, NEFH, NID2, PCDHB15, PCDHGA12, PFKP, PGRMC1, PHACTR3, PHKA2, POMC, PRKCA, PSEN1, RASSF1A, RASSF2, RBP1, RRAD, SFRP1, SGK, SOD3, SOX17, SULF2, TIMP3, TJP2, TRPV2, UCHL1, WDR69, ZFP42, ZNF442, and ZNF655.

The invention provides mutain of a human insulin-like growth factor conjugated protein 7 (IGFBP7). The mutain contains mutation of Arg198Ile / His200Phe, and has an amino acid sequence of SEQ ID NO.1. An igfbp7 gene coding sequence is selected from an SW480cDNA library of a human colorectal cancer cell line and is constructed into pET28a plasmids of a prokaryotic expression vector, so that the IGFBP7 protein can be expressed in a colon bacillus strain BL21. On the basis of the expression vector, mutain of the IGFBP7 is constructed, BL21 is converted, the mutain is expressed and purified, and a key site where the IGFBP7 is bonded with insulin is pointed out. The mutain provided by the invention has simple steps in a preparation method and high success rate, and the bonding capacity of the protein with insulin is remarkably reduced, so that insulin resistance can be suppressed and the mutain can be applied to the preparation of a medicament for treating type 2 diabetes.

The invention discloses a method and a kit for testing the carcass trait of a duck flock. The method for testing the carcass trait of the duck flock comprises: detecting haptotype, which is formed by SNP, of a duck IGFBP7 gene; and judging the haptotype gene of a duck sample to be tested and determining the carcass trait of the duck. The kit provided by the invention comprises PCR amplification primers for specifically amplifying the IGFBP7 gene and other PCR amplification agents. The method and the kit of the invention have simple and quick operation, and stable and reliable result. When used in assisted breeding screening, the method and the kit have the advantages of early screening, time conservation, low cost and high accuracy. The method and the kit have a promising application prospect in meat duck breeding practice.

Described is a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and / or of hospitalization due to chronic heart failure and / or death. The method is based on the determination of at least one biomarker selected from B-type natriuretic peptide (BNP) or N-terminal pro B-type natriuretic peptide (NT-proBNP), IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject along with the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy.

The purpose of the present invention is to provide a novel biomarker with which it is possible to accurately detect an aortic aneurysm. Specifically, the present invention pertains to an aortic aneurysm detection marker which contains an NPC2 (Niemann-Pick disease type C2) protein and / or an IGFBP7 (Insulin-like growth factor-binding protein 7) protein.

The present invention relates to a method for predicting the risk of stroke of a subject and to a method for improving the prediction accuracy of a clinical stroke risk score. The methods of the present invention are based on the determination of the amount of Angiopoietin-2 (Ang-2) and / or the amount of Insulin-like growth factor-binding protein 7 (IGFBP7) in a sample from a subject. Moreover, thepresent invention pertains to the use of i) the biomarker Ang-2 and / or the biomarker IGFBP7, and / or ii) at least one detection agent that specifically binds to Ang-2 and / or at least one detection agent that specifically binds to IGFBP7 in a sample from a subject for predicting the risk of stroke of said subject.

This invention provides a method of comparing disease markers obtained from subject samples to test for, detect, or diagnose autosomal dominant polycystic kidney disease and a disease marker for such disease. The method for detecting autosomal dominant polycystic kidney disease and the method for screening for an agent for treatment or prevention of such disease comprise detecting a gene that is expressed specifically in cases of autosomal dominant polycystic kidney disease, including IGFBP7.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a measured urine concentration of one or more of TIMP2 and IGFBP7 in combination with one or more of a measured serum creatinine and a measured urine output, which results are correlated to the renal status of the subject, and can be used for diagnosis, prognosis, risk stratification, staging, monitoring, categorizing and determination of further diagnosis and treatment regimens in subjects suffering or at risk of suffering from an injury to renal function, reduced renal function, and / or acute renal failure.

Provided are a pharmaceutical composition for prevention and treatment of a neural disease including at least one selected from the group consisting of mesenchymal stem cells (MSCs), a culture solution of the MSCs, activin A, PF4, decorin, galectin 3, GDF15, glypican 3, MFRP, ICAM5, IGFBP7, PDGF-AA, SPARCL1, thrombospondin-1, WISP1, progranulin, IL-4, a factor inducing expression thereof, and any combination thereof, and a method therefor.

The purpose of the present invention is to provide a novel biomarker for detecting an arteriosclerosis-related disease or for assessing the progress of arteriosclerosis. Specifically, the present invention pertains to a marker which includes Niemann-Pick disease type C2 (NPC2) protein and / or insulin-like growth factor-binding protein 7 (IGFBP7) protein, and which is for detecting an arteriosclerosis-related disease or for assessing the progress of arteriosclerosis.

The present invention provides methods and compositions for identifying patients at risk of kidney injury. A risk score, which is a composite of a urinary concentration of IGFBP7 (insulin-like growth factor-binding protein 7) and a urinary concentration of TIMP-2 (tissue inhibitor of metalloproteinase 2), is determined obtained from the patient, and is used to manage patient treatment.

The invention provides an application of a tumor inhibiting factor menin to diagnosis and treatment of pancreatic cancer. The mechanism that the menin factor inhibits growth of pancreatic cancer cells through overexpression is elaborated; on one hand, the menin factor inhibits growth of the pancreatic cancer cells by inhibiting expression of up-regulated genes p18, p27, HOXA9, HDAC5 and CBX4 and expression of down-regulated genes CDK2, CDK4, ESM1, IGFBP7 and GAS1; on the other hand, the menin factor is competitively combined with Dnmt1 to reduce the DNA methylation level of p18 / p27 promoters and promotes transcription of p18 / p27 genes to inhibit growth of the pancreatic cancer cells, and a new way is provided for treating the pancreatic cancer.

The invention belongs to the field of biological medicine, and mainly relates to application of a vascular secretion factor in preparation of a biomarker for detecting non-alcoholic steatohepatitis. The invention provides an application of a vascular secretion factor in preparation of a biomarker for detecting non-alcoholic steatohepatitis, and is characterized in that the vascular secretion factor comprises IGFBP7 and / or ADAMTS1; the IGFBP7 and / or the ADAMTS1 are / is expressed in an HDAC2 (histone deacetylase 2) / DNMT1-IGFBP7 / ADAMTS1-Th17 signal channel. The invention also provides application of the vascular secretion factor in preparation of the biomarker for distinguishing the non-alcoholic steatohepatitis and the simple fatty liver, and is characterized in that the vascular secretion factor comprises IGFBP7 and / or ADAMTS1; the IGFBP7 and / or the ADAMTS1 are / is expressed in an HDAC2 (histone deacetylase 2) / DNMT1-IGFBP7 / ADAMTS1-Th17 signal channel. The invention further provides application of the synergistic effect of the IGFBP7 and / or the ADAMTS1 in preparation of the biomarker for detecting the non-alcoholic steatohepatitis. According to the application provided by the invention, the non-alcoholic steatohepatitis can be evaluated more reliably, simply, conveniently and noninvasively.

The present invention provides methods and compositions for managing renal replacement therapy. A risk score, which is determined from a urinary concentration of IGFBP7 (insulin-like growth factor-binding protein 7) and / or a urinary concentration of TIMP-2 (tissue inhibitor of metalloproteinase 2), is determined obtained from the patient, and is used to manage patient treatment.